MarketPeel
Insider Trading Intelligence
GS

George A. III Samuel

LCTX
GENERAL COUNSEL/SECRETARY · LINEAGE CELL THERAPEUTICS, INC. · CIK 0001878732
FILING MIX · LIFETIME59%/41%
BUYS
13
SELLS
9
TOTAL VALUE
$21.2K
COMPANIES
1
ACTIVE SINCE
Sep 2021
HOLDINGS NOW
900,000
AVG SELL PX
$1.23
TRADE KIND
SHOWING 22 / 22
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by George A. III Samuel, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-9.62%+0.54%-10.16%-10.16%
14d1+100.00%+0.40%+0.36%+0.04%+0.04%
30d1+0.00%-16.53%+0.45%-16.98%-16.98%
60d1+100.00%+5.12%+1.56%+3.56%+3.56%
90d1+100.00%+9.64%-0.24%+9.88%+9.88%
180d1+100.00%+15.70%-2.97%+18.67%+18.67%
1y1+100.00%+182.65%+13.88%+168.76%+168.76%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LCTX · 900,000 shares · as of Mar 5, 2026
0225,000450,000675,000900,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 13 buys / 9 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
900,000900,000Mar 5, 2026Mar 6, 2026View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel and Secretary
6,0750Feb 11, 2026Feb 13, 2026View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASE
General Counsel and Secretary
6,07533,565Feb 11, 2026Feb 13, 2026View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel and Secretary
2,502$1.80$4.5K31,063Feb 11, 2026Feb 13, 2026View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,73527,555Dec 19, 2025Dec 19, 2025View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel and Secretary
65$1.68$10927,490Dec 19, 2025Dec 19, 2025View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
750,000750,000Mar 10, 2025Mar 12, 2025View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel
6,0766,075Feb 11, 2025Feb 12, 2025View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASE
General Counsel
6,07628,260Feb 11, 2025Feb 12, 2025View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel
2,440$0.65$1.6K25,820Feb 11, 2025Feb 12, 2025View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASE
General Counsel
15,000$0.60$9.0K22,184Nov 26, 2024Nov 26, 2024View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
650,000650,000Mar 7, 2024Mar 8, 2024View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel/Secretary
2,490$1.08$2.7K7,184Feb 11, 2024Feb 12, 2024View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASE
General Counsel/Secretary
6,0769,674Feb 11, 2024Feb 12, 2024View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel/Secretary
6,07612,151Feb 11, 2024Feb 12, 2024View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
650,000650,000Mar 9, 2023Mar 10, 2023View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel/Secretary
6,07618,227Feb 11, 2023Feb 14, 2023View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASE
General Counsel/Secretary
6,0766,076Feb 11, 2023Feb 14, 2023View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
SALE
General Counsel/Secretary
2,478$1.35$3.3K3,598Feb 11, 2023Feb 14, 2023View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
650,000650,000Mar 10, 2022Mar 11, 2022View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
24,30324,303Feb 11, 2022Feb 15, 2022View →
LCTX
LINEAGE CELL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
695,000695,000Sep 1, 2021Sep 2, 2021View →
Other insiders · LCTX
Loading peer insiders…
About this filer
CIK 0001878732
ROLE
General Counsel/Secretary
PRIMARY
LCTX
COMPANIES
1
ACTIVE SINCE
Sep 2021
MARKETPEEL · /INSIDER/0001878732DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback